Not good1 Feb 2022 12:48
Little barriers to entry in an already saturated market. No clinical science behind the products. The product is similar to a Ponzi scheme in essential oils. Shares being issued like confetti with up listing speculation keeping people holding on to a freefall. Management know this but simply don't care. They're just keeping it afloat for £250k+ a year.